Comparative pharmacoepidemiological characteristics of antibacterial drugs prescriptions used in patients with lower respiratory tract infection in a typical practice in Kursk and Chisinau

Objective: to study the structure of medical prescriptions for antibacterial drugs used in patients with various types of infection of the bronchopulmonary system in the conditions of typical practice in Kursk (Russian Federation) and Chisinau (Republic of Moldova). Materials and methods. In order to assess the structure of prescribing various classes of antibacterial agents used to treat patients with infections of the respiratory system, a survey of doctors from medical organizations in Kursk and Chisinau was conducted in the period from October 2019. to January 2020 as a one-time descriptive study. As model diseases are taken: acute bronchitis with purulent sputum, exacerbation of chronic obstructive pulmonary disease with purulent sputum, non-severe community-acquired pneumonia. Results. The leaders in prescription for acute bronchitis with purulent sputum were cephalosporins: in Kursk, their share was 24% (cefixime was most often prescribed), and in Chisinau, 26.8% (leaders were cefixime and ceftriaxone). In patients with exacerbation of chronic obstructive pulmonary disease and purulent sputum, doctors from both cohorts also more often recommended cephalosporins: 29.4% and 36.1% for Kursk and Chisinau, respectively; among them, cefixime, ceftriaxone and cefotaxime were leaders in Kursk, while ceftriaxone, cefotaxime and cefuroxime axetil were the priorities in Chisinau. For non-severe community-acquired pneumonia, doctors in Kursk preferred macrolides (more often - azithromycin and clarithromycin), inhibitor-protected penicillins (more often - amoxicillin/clavulanate) and cephalosporins (mainly of the 3rd generation), in Chisinau, cephalosporins (mainly of the 3rd generation) and penicillins (including inhibitor-protected) were more often prescribed, the proportion of macrolides was significantly less. Conclusion. Doctors from Chisinau and Kursk implement pharmacotherapy for this group of patients in accordance with modern clinical guidelines; at the same time, cases of irrational use of certain medicines are recorded.

1. Зайцев А.А. Современный взгляд на режимы антимикробной терапии внебольничных инфекций нижних дыхательных путей. Русский медицинский журнал. Медицинское обозрение. 2016;24(12):786-790. EDN: WHKNON.

2. Pneumonia comunitară la adult. Protocol clinic national. Chișinău. 2020. 39p. [Community-acquired Pneumonia in the adult. National clinical Protocol. Chisinau. 2020. 39 p. [(in Rom.)].

3. Bronhopneumopatia obstructivă cronică. Protocol clinic national. Chișinău. 2020. 39p. [Chronic obstructive bronchopneumopathy. National clinical Protocol. Chisinau. 2020. 39 p. [(in Rom.)].

4. Belevsky A.S., ed. Global strategy for the diagnosis, treatment and prevention of chronic obstructive pulmonary disease (revision 2014) translated. Moscow: Russian Respiratory Society, 2014: 92. (in Russ.)

5. Mavzyutova G.A., Kuzovkina O.Z., Galieva G.A., Khasanova G.F., Mavzyutova A.A. Etiological and immunological features of lower respiratory tract infections. Byulleten’ Orenburgskogo nauchnogo tsentra UrO RAN. 2019;(3):10 (in Russ.). DOI:10.24411/2304-9081-2019-13019. EDN: PXSAQB.

6. Sinopalnikov A. I.Community-acquired infections of the lower respiratory tract: approaches to rational antibacterial therapy. Bolezni organov dykhaniya. Prilozheniye k zhurnalu Consilium Medicum. 2017;(1):45-51 (in Russ.). DOI: 10.26442/2075-1753_19.11.1.45-51. EDN: ZSMBFN.

7. Sinopalnikov A. I. Antibiotics and community-acquired infections of the lower respiratory tract. To whom? Which one? Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2019;26(5):47-60 (in Russ.). DOI: 10.18565/pharmateca.2019.5.47-60. EDN: FXUBVI.

8. Sinopalnikov A.I., Romanovskikh A.G.Community-acquired lower respiratory tract infections in adults: diagnosis and antimicrobial chemotherapy. Effektivnaya farmakoterapiya. 2014;(40):28-43 (in Russ.). EDN: SXMYVL.

9. Lazareva N.B. Outpatient therapy of lower respiratory tract infections. Medical council. 2012;(3):8-11 (in Russ.). EDN: OYGCWL.

10. Zaitsev A. A. Epidemiology and pharmacotherapy of lower respiratory tract infections: the place of "protected" aminopenicillins. Medical council. 2018;(15):76-81 (in Russ.). DOI: 10.21518/2079-701X-2018-15-76-81. EDN: VBMBQX.

11. Kramarev S. A., Grechukha E.O. Aspects of the treatment of lower respiratory tract infections from the point of view of clinical guidelines from different countries (bronchiolitis, bronchitis, community-acquired pneumonia). Aktual’naya infektologiya. 2019;7(4):181-188 (in Russ.). DOI: 10.22141/2312-413x.7.4.2019.178878. EDN: IKNLSW

12. Bacinschi N., Pleșca C., Caracaș A., Vasilache E., Ștîrba D., Guțu I. Terapia antibacteriană a pneumoniilor comunitare. Buletinul Academiei de Știinţe a Moldovei. Știinţe medicale. 2021;1(69):116-120. [Bacinschi N., Plesca C., Caracas A., Vasilache E., Shtirba D, Gutu I. antibacterial therapy of community pneumonias. Bulletin of the Academy of Sciences of Moldova. Medical Sciences. 2021;1(69):116-120 (in Rom.)]. DOI: 10.52692/1857-0011.2021.1-69.

13. Borovikov, V. P., Borovikov I.P. Statistica: stat. data analysis and processing in the Windows environment. Moscow: Informatsionno-izdatel’skiy dom «Filin”», 1998. 608 p. (in Russ.)

14. Glants S. Medico-biological statistics. Moscow: Praktika, 1998. 459 p. (in Russ.)

15. Acute bronchitis in adults. Clinical recommendations. Moscow. 2022. 40p. (in Russ.)

16. Wark P. Bronchitis (acute). BMJ Clin Evid. 2015:1508.

17. Zaitsev A.A., Kulagina I.T. Pharmacotherapy of acute bronchitis. Consilium medicum. 2012;(14): 16-21 (in Russ.). EDN: RAIFPJ.

18. Mainous A.G. 3rd, Saxena S., Hueston W.J., Everett C.J., Majeed A. Ambulatory antibiotic prescribing for acute bronchitis and cough and hospital admissions for respiratory infections: time trends analysis. J R Soc Med. 2006;99(7):358-362. DOI: 10.1177/014107680609900719.

19. Dvoretsky L.I. Elderly patient with acute and chronic bronchitis: Key issues of antibacterial therapy. Pharmateca. 2015;6(299):39-45 (in Russ.). EDN: TQANER.

20. Filatova K. A. Pharmacoepidemiological analysis of antibacterial therapy of acute bronchitis in outpatient practice. Bulletin of medical Internet conferences. 2016;6(5):935 (in Russ.). EDN: XCYYPB.

21. Picazo J.J., Pеrez-Cecilia E., Herreras A., Grupo DIRA en Atenciоn Primaria. Respiratory infections outside the hospital. DIRA study. Enferm Infec Microbiol Clin. 2003;21:410-416. DOI: 10.1016/s0213-005x(03)72978-4.

22. Gonzales R., Steiner J.F., Sande M.A. Antibiotic prescribing for colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA. 1997;278:901-904.

23. Chronic obstructive pulmonary disease. Clinical recommendations. Moscow, 2021. 60p. (in Russ.)

24. Wilson R., Anzueto A., Miravitlles M., Arvis P., Alder J., Haverstock D., Trajanovic M., Sethi S. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J. 2012;40(1):17-27. DOI: 10.1183/09031936.00090311.

25. Yoon H.I., Lee C.H., Kim D.K., Park G.M., Lee S.M., Yim J.J., Kim J.Y., Lee J.H., et al. Efficacy of levofloxacin versus cefuroxime in treating acute exacerbations of chronic obstructive pulmonary disease.Int J Chron Obstruct Pulmon Dis. 2013;8:329-334. DOI: 10.2147/COPD.S41749.

26. The Global Strategy for Diagnosis, Management and Prevention of COPD (updated 2022), the Pocket Guide (updated 2022). 2022. 177p.

27. Vidyakina E.E., Malchikova S.V. The study of the typical practice of managing patients with chronic obstructive pulmonary disease at the outpatient stage. Prakticheskaya meditsina. 2016;3(95):22-24 (in Russ.). DOI: 10.21518/2079-701X-2016-19-158-160. EDN: WAIBUX.

28. Bochanova E.N., Zyryanov S.K., Demko I.V., Gordeeva N.V., Golovina N.I. Pharmacoepidemiology of antibacterial drugs in pulmonology (on the example of the Department of pulmonology of the regional clinical hospital). Clinical pharmacology and therapy. 2015;24(4):95-98 (in Russ.). EDN: VPRAPL.

29. Community-acquired pneumonia in adults. Clinical recommendations. Moscow. 2021. 96p. (in Russ.)

30. Deryushkin V.G., Ternavsky A.P., Ulyanova E.A., Gatsura S.V. The choice of an antibiotic for community-acquired pneumonia - the results of a survey of doctors and an analysis of real outpatient practice. Kachestvennaya klinicheskaya praktika. 2019;(4):50-54 (in Russ.). DOI 10.1016/2588-0519-2019-4-50-54. EDN: IPOVEA.

31. Deryushkin V.G., Ternavsky A.P., Gatsura S.V. Pharmacoeconomical analysis of the appointment of antimicrobial drugs of the first choice for outpatient treatment of mild community-acquired pneumonia. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya. 2020;13 (4):329-336 (in Russ.). DOI: 10.17749/2070-4909/farmakoekonomika.2020.048. EDN: BJOUME.

32. Trinh H.T., Hoang P.H., Cardona-Morrell M., Nguyen H.T., Vu D.H., Dong P.T., Cao T.T., Nguyen S.T., et al. Antibiotic therapy for inpatients with community-acquired pneumonia in a developing country. Pharmacoepidemiol Drug Saf. 2015;24(2):129-136. DOI: 10.1002/pds.3614.